Pharmacoepigenetics - 1st Edition - ISBN: 9780128139394

Pharmacoepigenetics, Volume 11

1st Edition

Series Volume Editors: Ramón Cacabelos
Hardcover ISBN: 9780128139394
Imprint: Academic Press
Published Date: 1st April 2019
Page Count: 624
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

Section I
1. Structure and function of the Epigenetic Machinery
2. Epigenetics in human disease
3. Basic Concepts in Pharmacoepigenomics
4. Current Epigenetic Drugs
5. Epigenetic mechanisms in the regulation of drug metabolism and transport
6. Impact of pharmacoepigenomics in drug efficiency and safety
7. Role of pharmacoepigenomics in interindividual differences in drug response
8. Pharmacoepigenomics of drug resistance

Section II
9. Epigenetics of cardiovascular disorders
10. Epigenetics of cancer
11. Epigenetics of major mental disorders
12. Epigenetics of neurological disorders
13. Epigenetics of cerebrovascular disorders
14. Epigenetics of age-related degenerative disorders

Section III
15. Pharmacoepigenetic considerations for the treatment of breast cancer
16. Pharmacoepigenomics of colorectal cancer
17. Pharmacoepigenomics of gastrointestinal tumors
18. Epigenetic strategies for the treatment of gynecological cancers
19. Pharmacoepigenetics of prostate cancer
20. Pharmacoepigenetics of liver cancer
21. Pharmacoepigenetics of lung cancer
22. Pharmacoepigenetics of age-related neurodegenerative diseases
23. Use of pharmacoepigenomics for next-generation treatment of neuropsychiatric disorders
24. Pharmacoepigenetics of depression
25. Pharmacoepigenetics of psychotic disorders
26. Epigenomics and pharmacoepigenomics involving heart failure and arrhythmia
27. Epigenetic-based immune intervention for rheumatic diseases
28. Pharmacogenomics and pharmacoepigenomics in pediatric medicine

Section-IV
29. Pharmacoepigenetics in personalized medicine
30. Pharmacoepigenetic procedures in drug development
31. DNA methyltransferase inhibitors
32. Histone acyltransferase modulators
33. Histone methyltransferase inhibitors
34. Histone demethylase inhibitors
35. MicroRNA Pharmacoepigenomics
36. Future prospects for the development of epigenetic drugs and the introduction of pharmacoepigenetic procedures in medical practice


Description

The last decade has seen a revolution in human genomics, both in technological innovation and the discovery of genetic biomarkers associated with disease. In parallel, steady progress in epigenetic research has demonstrated how epigenetic change and misregulation can have damaging effects resulting in chronic disease, cancer, age-associated illness, heart disease, neuropsychiatric disorders and many other disease types. In response, interest from the pharmaceutical industry to leverage pharmacoepigenetics for more effective and efficient clinical drug development is now stronger than ever before.

With Pharmacoepigenetics, Editors Ramón Cacabelos and Oscar Teijido have compiled the first applied, comprehensive volume on the role of epigenetics and epigenomics in drug discovery and development, providing a detailed but accessible view of the field from basic principles to application in disease therapeutics. Leading international researchers from across academia, clinical settings, and the pharmaceutical industry discuss the influence of epigenetics and epigenomics in human pathology; epigenetic biomarkers for disease prediction, diagnosis, and treatment; current epigenetic drugs and the application of epigenetic procedures in drug development; and the pharmacoepigenetics of cardiovascular disease, neuropsychiatric disorders, rheumatic disease, age-associated illness, and numerous cancers among other disease types. Here, researchers in academia and the pharmaceutical industry will discover guidelines and approaches for applying pharmacoepigenetics in drug development, efficiency, and safety, and learn to adopt the latest epigenetic advances to realize new precision therapies. Throughout the book, chapter authors offer a balanced and objective discussion of the future of pharmacoepigenetics and its crucial contribution to the growth of precision and personalized medicine.

Key Features

  • Fully examines the influence of epigenetics and epigenomics in human pathology; epigenetic biomarkers for disease prediction, diagnosis, and treatment; current epigenetic drugs and the application of epigenetic procedures in drug development; and the pharmacoepigenetics of cardiovascular disease, neuropsychiatric disorders, rheumatic disease, age-related disease, and numerous cancers
  • Features chapter contributions from leading international researchers in academia, clinical settings, and the pharmaceutical industry
  • Instructs researchers, students, and clinicians on how to better interpret and employ pharmacoepigenetics in drug development, efficiency, and safety, adopting the latest epigenetic advances to realize new precision therapies
  • Provides a balanced and objective discussion of the future of pharmacoepigenetics and its crucial role in precision medicine

Readership

Translational researchers, clinicians and graduate students in genomic medicine, epigenetics; life science researchers; developmental biologists; MDs/clinicians; pharmacologists in industry and academia; cardiologists, psychiatrists, oncologists, hospitalists, primary care doctors, neurologists, immunologists, medical chemists, molecular biologists


Details

No. of pages:
624
Language:
English
Copyright:
© Academic Press 2019
Published:
Imprint:
Academic Press
Hardcover ISBN:
9780128139394

Ratings and Reviews


About the Series Volume Editors

Ramón Cacabelos Series Volume Editor

Dr. Ramón Cacabelos is Professor and Chairman of Genomic Medicine and President of the EuroEspes Biomedical Research Center, Corunna, Spain. He received his M.D. from Oviedo University, Oviedo, Spain; Ph.D. from Santiago University, Santiago de Compostela, Spain; and D.M.Sci. (Psychiatry) from Osaka University Medical School, Osaka, Japan. After a decade at the Department of Psychiatry in Osaka, he returned to Spain and focused his research activity on the genomics, epigenomics and pharmacogenomics of brain disorders, with special emphasis on neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease). He has published over 700 papers and 30 books and is Editor-in-Chief of the first World Guide for Drug Use and Pharmacogenomics and President of the World Association of Genomic Medicine.

Affiliations and Expertise

Professor of Genomic Medicine, Visiting Professor of Health Science, Aino University, Osaka, Japan, President, World Association of Genomic Medicine, President, Spanish Society of Genomic Medicine